Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine Acetamide SCHEMBL29431271 | 1.00 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| Pyridine Acetamide SCHEMBL7432558 | 0.98 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| Pyridine Acetamide SCHEMBL3723681 | 0.98 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| Pyridine Acetamide SCHEMBL5709841 | 0.98 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| Pyridine Acetamide SCHEMBL10410418 | 0.91 | RAB9A (0.47) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| Pyridine Acetamide SCHEMBL2791176 | 0.88 | POLB (0.48) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| Pyridine Acetamide SCHEMBL3716648 | 0.88 | RAB9A (0.49) | RAB9ANPC1SMN1; SMN2PARP10PTPRA | |
| Pyridine Acetamide SCHEMBL11215815 | 0.85 | LOXL2 (0.48) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| Pyridine Acetamide SCHEMBL4060557 | 0.84 | RAB9A (0.42) | RAB9ANPC1SMN1; SMN2PARP10HRH1 | |
| SCHEMBL7890891 | 0.83 | HRH1 (0.54) | RAB9ANPC1SMN1; SMN2PARP10HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 967 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4301736-B1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | LEAD DISCOVERY CENTER GMBH (DE) | 2025-10-08 | — | — | EP | claimed |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | claimed |
| US-20240270748-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2024-08-15 | — | — | US | claimed |
| CN-117603604-B | Preparation method of printing gloss oil with amino-terminated hyperbranched self-assembled polyamide as main component | 江苏众立生包装科技有限公司 | 2024-05-24 | — | — | CN | claimed |
| CN-117653636-B | Anticancer medicine containing condensed bicyclo compound and pharmaceutical use of the compound | 上海瑛派药业有限公司 | 2024-04-26 | — | — | CN | claimed |
| CN-117603604-A | Preparation method of printing gloss oil with amino-terminated hyperbranched self-assembled polyamide as main component | 江苏众立生包装科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| US-20230227458-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, INC. | 2023-07-20 | — | — | US | claimed |
| EP-4155296-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | Lead Discovery Center GmbH (DE) | 2023-03-29 | — | — | EP | claimed |
| CN-109563085-B | Piperidine CXCR7 receptor modulators | 爱杜西亚药品有限公司 | 2022-08-09 | — | — | CN | claimed |
| US-20220169627-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | BIOMEA FUSION, LLC | 2022-06-02 | — | — | US | claimed |
| EP-0489308-B1 | Partricin derivatives | PRODOTTI ANTIBIOTICI SPA (IT) | 1998-09-02 | — | — | EP | claimed |
| EP-0434943-B1 | Polyene macrolide derivatives | PRODOTTI ANTIBIOTICI SPA (IT) | 1995-09-06 | — | — | EP | claimed |
| US-5298495-A | Partricin derivatives | SPA SOCIETA' PRODOTTI ANTIBIOTICI SPA (IT) | 1994-03-29 | — | — | US | claimed |
| US-5296597-A | Antibiotics | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.P.A. (IT) | 1994-03-22 | — | — | US | claimed |
| EP-0497835-A1 | METHOD FOR TREATING HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR | THE UPJOHN COMPANY (US) | 1992-08-12 | — | — | EP | claimed |
| EP-0489308-A1 | Partricin derivatives | SPA SOCIETA' PRODOTTI ANTIBIOTICI S.p.A. (IT) | 1992-06-10 | — | — | EP | claimed |
| EP-0434943-A1 | Polyene macrolide derivatives | S P A SOCIETA' PRODOTTI ANTIBIOTICI S.p.a. (IT) | 1991-07-03 | — | — | EP | claimed |
| WO-1991006561-A1 | METHOD FOR TREATING HIV AND OTHER RETROVIRUSES AND COMPOUNDS USEFUL THEREFOR | THE UPJOHN COMPANY (US) | 1991-05-16 | — | — | WO | claimed |
| EP-0375451-A2 | Compounds having a renin-inhibiting activity | BEECHAM GROUP PLC (GB) | 1990-06-27 | — | — | EP | claimed |
| EP-0014569-B1 | (-)-ALPHA-(2-(BIS(1-METHYLETHYL)AMINO)ETHYL)-ALPHA-PHENYL-2-PYRIDINEACETAMIDE AND PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PRODUCTION THEREOF AND COMPOSITIONS CONTAINING THE SAME | G.D. Searle & Co. (US) | 1983-07-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240270748-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | RAB9A 1733/4885NPC1 2278/4885SMN1; SMN2 3963/4885 |
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | RAB9A 75/4885NPC1 620/4885SMN1; SMN2 60/4885 |
| US-20230227458-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | RAB9A 2519/4885NPC1 3981/4885SMN1; SMN2 2125/4885 |
| US-20220169627-A1 | IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | RAB9A 2519/4885NPC1 3981/4885SMN1; SMN2 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.